Goldman Sachs, H.C. Wainwright Maintain Buy on ImmunityBio, Inc. (IBRX) Feb 2026
IBRX analyst rating: Goldman Sachs and H.C. Wainwright maintained Buy on ImmunityBio, Inc. (IBRX) on February 23, 2026. The dual maintenance keeps consensus support steady while H.C. Wainwright raised its price target to $15 from $10. The actions arrive alongside recent share weakness of roughly -12%, which frames the analyst views as endorsements rather than momentum calls. We examine the rating details, price target change, firm rationales, and what these updates mean for investors monitoring IBRX analyst rating as part of their research.
IBRX analyst rating: February 23, 2026 summary
Goldman Sachs and H.C. Wainwright both maintained Buy for ImmunityBio, Inc. (IBRX) on February 23, 2026. H.C. Wainwright also raised its price target to $15 from $10 the same day. The StreetInsider post and TheFly summary reported the H.C. Wainwright update publicly source source.
IBRX price target change and firm rationale
H.C. Wainwright moved its price target to $15 from $10, signaling stronger upside assumptions. That firm cited updated model inputs and treatment potential as drivers for the raise. Goldman Sachs kept its Buy stance without a published target in these updates, preserving its prior view of upside tied to pipeline progress.
What the maintained Buy ratings mean for investors
A maintained Buy means analysts see continued upside versus current market levels despite recent weakness. For risk-tolerant investors this signals that analysts expect future data or commercial progress to reverse the recent ~12% drop. For conservative investors the maintained rating is not a guarantee and should be weighed with clinical, regulatory, and cash runway risks specific to ImmunityBio.
Historical analyst coverage and context for IBRX analyst rating
Analyst coverage of ImmunityBio has been intermittent but includes major names such as Goldman Sachs and specialist firms like H.C. Wainwright. The H.C. Wainwright target reset to $15 is the most notable change on February 23, 2026. Market cap for ImmunityBio stands at $9,682,205,950, which keeps the stock in the mid-cap biotech range and underlines why selective analyst attention persists.
How ratings link to IBRX stock moves
The public updates came as the stock showed declines of about -12.05% and -12.1% in the cited notes. That disconnect can reflect timing, with analysts focusing on longer-term fundamentals while the market reacts to short-term news or sentiment. Investors should watch trading volume and upcoming catalysts to see if the analyst view aligns with renewed buying interest.
Meyka AI grade and practical next steps
Meyka AI rates IBRX with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. We recommend investors combine the IBRX analyst rating with model checks on cash runway, trial timelines, and recent data. Meyka AI is an AI-powered market analysis platform that tracks these metrics in real time.
Final Thoughts
Key takeaways on the IBRX analyst rating are straightforward. On February 23, 2026, Goldman Sachs and H.C. Wainwright maintained Buy, and H.C. Wainwright raised its price target to $15 from $10. The moves keep analyst sentiment constructive as the stock trades lower by about 12%, suggesting analysts look past near-term volatility toward pipeline milestones.
Investors should treat the maintained Buy ratings as informed opinions, not guarantees. The IBRX analyst rating update provides a positive reference point, but investors must weigh clinical risk, regulatory timelines, and capital needs. Meyka AI rates IBRX B+, reflecting both upside potential and biotech risk. This grade is not investment advice.
FAQs
What changed in the IBRX analyst rating on February 23, 2026?
On February 23, 2026 Goldman Sachs and H.C. Wainwright maintained Buy on ImmunityBio. H.C. Wainwright also raised its price target to $15 from $10, reinforcing a positive analyst bias for IBRX analyst rating.
How should investors interpret the H.C. Wainwright price target raise?
The raise to $15 signals stronger upside assumptions from H.C. Wainwright. Investors should view it as increased analyst confidence but confirm assumptions against trial timelines and cash runway when assessing the IBRX analyst rating.
Does the maintained Buy mean IBRX stock will rise soon?
A maintained Buy is an analyst view, not a timing signal. It suggests upside over a medium term. Short-term moves can still go against analysts, so pair the IBRX analyst rating with catalysts and risk checks.
What is Meyka AI’s current assessment of IBRX?
Meyka AI rates IBRX with a B+. This grade blends sector performance, financial growth, analyst consensus, and benchmark comparisons but is not financial advice for trading based on the IBRX analyst rating.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.